Souria Dougherty

587 total citations
21 papers, 102 citations indexed

About

Souria Dougherty is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Souria Dougherty has authored 21 papers receiving a total of 102 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 16 papers in Hematology and 2 papers in Molecular Biology. Recurrent topics in Souria Dougherty's work include Acute Myeloid Leukemia Research (14 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Souria Dougherty is often cited by papers focused on Acute Myeloid Leukemia Research (14 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Souria Dougherty collaborates with scholars based in United States, Italy and Germany. Souria Dougherty's co-authors include Laurie Sherman, Rami S. Komrokji, Fei Huang, Faye Feller, Tymara Berry, Ying Wan, John Mascarenhas, Jean‐Jacques Kiladjian, Aleksandra Rizo and Olatoyosi Odenike and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Souria Dougherty

18 papers receiving 100 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Souria Dougherty United States	6	75	73	54	17	16	21	102
Xénia Cabagnols France	3	30 0.4×	36 0.5×	60 1.1×	9 0.5×	6 0.4×	3	74
A. M. Vannucchi Italy	4	61 0.8×	33 0.5×	21 0.4×	3 0.2×	10 0.6×	14	81
Iwan Buetti Italy	3	80 1.1×	72 1.0×	12 0.2×	27 1.6×	8 0.5×	7	122
Liesl Mathias United Kingdom	3	52 0.7×	59 0.8×	21 0.4×	7 0.4×	4 0.3×	3	82
Mihaela Lazaroiu Singapore	5	46 0.6×	51 0.7×	31 0.6×	13 0.8×	3 0.2×	9	59
Allison Pike United States	6	82 1.1×	57 0.8×	52 1.0×	18 1.1×		9	93
Yervand Hakobyan Armenia	4	16 0.2×	32 0.4×	10 0.2×	47 2.8×	11 0.7×	13	66
Fausto Palmieri Italy	2	41 0.5×	57 0.8×	42 0.8×	20 1.2×	1 0.1×	5	75
Louise MacGillivray United Kingdom	2	44 0.6×	25 0.3×	19 0.4×	3 0.2×	3 0.2×	2	60
Laurent Garderet France	2	43 0.6×	25 0.3×	10 0.2×	4 0.2×	2 0.1×	4	47

Countries citing papers authored by Souria Dougherty

Since Specialization

Citations

This map shows the geographic impact of Souria Dougherty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Souria Dougherty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Souria Dougherty more than expected).

Fields of papers citing papers by Souria Dougherty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Souria Dougherty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Souria Dougherty. The network helps show where Souria Dougherty may publish in the future.

Co-authorship network of co-authors of Souria Dougherty

This figure shows the co-authorship network connecting the top 25 collaborators of Souria Dougherty. A scholar is included among the top collaborators of Souria Dougherty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Souria Dougherty. Souria Dougherty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jiang, Zhubo, et al.. (2025). VALIDATION OF A DEEP LEARNING-BASED ALGORITHM IN QUANTIFYING TRICUSPID VALVE REGURGITATION. Journal of the American College of Cardiology. 85(12). 2066–2066.

Mascarenhas, John, Salman Otoukesh, Terrence Bradley, et al.. (2024). Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF). Blood. 144(Supplement 1). 998–998. 1 indexed citations

Sekeres, Mikkael A., Valeria Santini, Amer M. Zeidan, et al.. (2024). Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial. Blood. 144(Supplement 1). 3210–3210.

Sekeres, Mikkael A., Valeria Santini, María Díez‐Campelo, et al.. (2024). Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study. Leukemia & lymphoma. 66(3). 529–534. 2 indexed citations

Kuykendall, Andrew, Terrence Bradley, Rami S. Komrokji, et al.. (2023). PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF. HemaSphere. 7(S3). e906057e–e906057e. 1 indexed citations

Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2023). PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF). HemaSphere. 7(S3). e99899f4–e99899f4. 1 indexed citations

Sekeres, Mikkael A., María Díez‐Campelo, Amer M. Zeidan, et al.. (2023). Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial. Blood. 142(Supplement 1). 6479–6479.

Zeidan, Amer M., Uwe Platzbecker, Valeria Santini, et al.. (2023). IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).. Journal of Clinical Oncology. 41(16_suppl). 7004–7004. 4 indexed citations

Platzbecker, Uwe, Rami S. Komrokji, Pierre Fenaux, et al.. (2022). Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study. Blood. 140(Supplement 1). 1106–1108. 6 indexed citations

10.

Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2022). P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR. HemaSphere. 6. 938–939. 1 indexed citations

11.

Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2022). Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncology. 18(22). 2393–2402. 22 indexed citations

12.

Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2022). MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor. Blood. 140(Supplement 1). 6826–6829. 1 indexed citations

13.

Santini, Valeria, Pierre Fenaux, Koen Van Eygen, et al.. (2021). On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). Blood. 138(Supplement 1). 2598–2598. 4 indexed citations

14.

Platzbecker, Uwe, Rami S. Komrokji, Pierre Fenaux, et al.. (2021). IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment.. Journal of Clinical Oncology. 39(15_suppl). TPS7056–TPS7056. 3 indexed citations

15.

Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2021). A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi). Blood. 138(Supplement 1). 1503–1503. 1 indexed citations

16.

Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2020). A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor. Blood. 136(Supplement 1). 43–44. 7 indexed citations

17.

Kiladjian, Jean‐Jacques, John Mascarenhas, Rami S. Komrokji, et al.. (2020). Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis. Blood. 136(Supplement 1). 45–46. 1 indexed citations

18.

Mascarenhas, John, Rami S. Komrokji, Michèle Cavo, et al.. (2020). Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients. Blood. 136(Supplement 1). 39–40. 9 indexed citations

19.

Platzbecker, Uwe, David P. Steensma, Koen Van Eygen, et al.. (2019). Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood. 134(Supplement_1). 4248–4248. 5 indexed citations

20.

Mascarenhas, John, Rami S. Komrokji, Michèle Cavo, et al.. (2018). Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels. Blood. 132(Supplement 1). 685–685. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact